Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $4.4 million.

  • Cumberland Pharmaceuticals' Cost of Revenue rose 82.66% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 254.95%. This contributed to the annual value of $17.0 million for FY2024, which is 774.31% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Cost of Revenue stood at $4.4 million, which was up 82.66% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Cost of Revenue ranged from a high of $4.8 million in Q4 2023 and a low of $3.3 million during Q4 2021
  • For the 5-year period, Cumberland Pharmaceuticals' Cost of Revenue averaged around $4.2 million, with its median value being $4.2 million (2025).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Cost of Revenue skyrocketed by 4082.92% in 2023, and later plummeted by 1127.65% in 2024.
  • Cumberland Pharmaceuticals' Cost of Revenue (Quarter) stood at $3.3 million in 2021, then increased by 2.22% to $3.4 million in 2022, then soared by 40.83% to $4.8 million in 2023, then fell by 11.28% to $4.2 million in 2024, then rose by 5.0% to $4.4 million in 2025.
  • Its Cost of Revenue was $4.4 million in Q3 2025, compared to $4.2 million in Q2 2025 and $4.2 million in Q1 2025.